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Abstract
Background
With the scale-up of antiretroviral therapy (ART), monitoring programme performance is
needed to maximize ART efficacy and limit HIV drug resistance (HIVDR).
Methods
We implemented aWHO HIVDR prospective survey protocol at three treatment centers
between 2012 and 2013. Data were abstracted from patient records at ART start (T1) and
after 12 months (T2). Genotyping was performed in the HIV pol region at the two time
points.
Results
Of the 425 patients enrolled, at T2, 20 (4.7%) had died, 66 (15.5%) were lost to follow-up,
313 (73.6%) were still on first-line, 8 (1.9%) had switched to second-line, 17 (4.0%) had
transferred out and 1 (0.2%) had stopped treatment. At T2, 272 out of 321 on first and sec-
ond line (84.7%) suppressed below 1000 copies/ml and the HIV DR prevention rate was
70.1%, just within the WHO threshold of70%. The proportion of participants with potential
HIVDR was 20.9%, which is higher than the 18.8% based on pooled analyses from African
studies. Of the 35 patients with mutations at T2, 80% had M184V/I, 65.7% Y181C, and
48.6% (54.8% excluding those not on Tenofovir) had K65Rmutations. 22.9% had Thymi-
dine Analogue Mutations (TAMs). Factors significantly associated with HIVDR prevention
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at T2 were: baseline viral load (VL) <100,000 copies/ml [Adjusted odds ratio (AOR) 3.13,
95% confidence interval (CI): 1.36–7.19] and facility. Independent baseline predictors for
HIVDR mutations at T2 were: CD4 count <250 cells/μl (AOR 2.80, 95% CI: 1.08–7.29) and
viral load100,000 copies/ml (AOR 2.48, 95% CI: 1.00–6.14).
Conclusion
Strengthening defaulter tracing, intensified follow-up for patients with low CD4 counts and/
or high VL at ART initiation together with early treatment initiation above 250 CD4 cells/ul
and adequate patient counselling would improve ART efficacy and HIVDR prevention. The
high rate of K65R and TAMs could compromise second line regimens including NRTIs.
Introduction
The 2010 guidelines recommended ART initiation for all patients with a CD4 count of350
cells/mm3 and for those with WHO clinical stage 3 or 4 if CD4 testing is not available. In
Uganda, applying these guidelines, the proportion of all ART-eligible patients receiving treat-
ment was 69.4% i.e. 570,373 by the end of September 2013. However, this proportion falls to
40.0% if the 2013 WHO guidelines for ART eligibility are used [1]. The 2013 ARV guidelines
recommend initiating ART earlier—at CD4 count500 cells/mm3– and immediately initiat-
ing ART for sero-discordant couples, pregnant women living with HIV, people with TB and
HIV, people with HIV and hepatitis B, and children living with HIV who are younger than five
years, irrespective of CD4 cell count. While in well-resourced countries monitoring of people
on ART is individualized and includes VL and resistance testing, in resource limited countries,
WHO recommends a public health approach to ART delivery with limited laboratory monitor-
ing [2].
Uganda’s national treatment guidelines are in line with WHO public health guidelines and
comprise simplified clinical and laboratory criteria to determine ART eligibility, and standard
therapeutic algorithms based on standardized first and second—line ART regimens. More
recently, these guidelines have been revised [3] to reflect the new 2013 WHO guidelines. The
nationally recommended treatment regimens contain 1 non-nucleoside reverse transcriptase
inhibitor (NNRTI) with 2 nucleoside reverse transcriptase inhibitors (NRTIs), with a recent
recommendation for TDF to be the first line drug of choice replacing AZT, partly due to its
lower toxicity levels and the availability of a single pill containing TDF and FTC. Although the
new guidelines also recommend VL as the preferred monitoring approach to diagnose and
confirm ARV treatment failure, VL testing is not being performed in most treatment centers
because of cost and limited availability. Instead CD4 count and clinical monitoring are used to
diagnose treatment failure, although due to inadequate resources even the recommended CD4
counts are not always performed.
The current ART delivery in Uganda under the WHO public health approach lacks a robust
system to monitor the success of the programme in suppressing VL and minimizing HIVDR.
For that reason, WHO has provided guidelines for countries to implement HIV ART resistance
prevention, monitoring and surveillance activities to monitor ART resistance that is transmit-
ted among drug naïve populations, and monitor development of resistance and associated fac-
tors in those on treatment[4,5]. Following these guidelines, we have reported low to moderate
transmitted drug resistance (TDR) in Uganda, 0/46 (0%), 6/70 (8.6%), 1/40 (2.5%) and 3/47
(6%), [6–9] For those on treatment, the WHO protocol is designed to use standardized,
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minimum-resource methodology to assess the success of adult and paediatric ART sites in pre-
venting HIVDR emergence during the first year of ART. The surveys also identify associated
factors that can be addressed at the level of the ART site or programme. Their objectives
include estimation of the proportion of HIV-1 positive adults enrolled on ART achieving viral
suppression after taking standard first-line ART for 12 months, identification of specific
HIVDR mutation patterns among populations not achieving viral suppression after 12 months
of taking standard first-line ART and to assess the association between individual and pro-
grammatic factors and viral suppression and HIVDR mutations and mutation patterns[10].
There are a number of countries that have implemented these protocols [11–16]. These surveys
have been identified as the best method of identifying the emergence of HIVDR in resource-
limited countries at the population level when it is impractical to look at the individual patient
level. Whereas no previous studies have reported results based on the standardized WHO pro-
tocol to assess acquired drug resistance in Ugandan adults, one prospective cohort study in six
African countries has reported very high rates of resistance in pre-treatment patients in
Uganda probably related to the earlier ART roll out in Uganda [17]. Overall good viral suppres-
sion was reported at 12 months in the six countries [18].
With Uganda’s HIV/AIDS burden at 1.6 million according to the 2014 Ministry of Health
report and with the efforts to increase the number of patients on ART including test and treat
for key populations such as sex workers and fisher folk, numbers on ART are expected to
exceed 1.2 million, by 2020. There were about 750,000 patients on ART by March 2015 accord-
ing to Ministry of health (report in draft). With such large numbers of patients, there is an
urgent need to minimize preventable HIVDR at the programme level. It is therefore critical to
have prospective data in a variety of health settings to effectively monitor HIVDR and identify
risk factors that might hamper success of the ART programme in Uganda. These efforts are
now part of the new National HIV/AIDS strategic plan 2015/2016-2019/2020 [19].
The overall objective of our pilot study therefore was to implement the standardized WHO
approach to monitoring of HIVDR emerging during ART, and associated programme factors,
in three health facilities in Uganda.
Methods
Study design and population
A prospective cohort survey based on the WHO generic protocol [10] for monitoring acquired
HIVDR was conducted at three sentinel health facilities during the period between March 2012
and November 2013. A blood specimen and minimal data were collected at baseline when
ART was initiated (T1), and at follow-up i.e. 12 months after ART start and assessed for VL
and HIVDR mutations (HIVDRMs). We allowed an additional 3 months to ascertain loss to
follow up (LTFU). The study clinics traced patients who missed their scheduled visits mainly
through phone calls. Visits to patients’ homes were also done by one of the health facility care
teams when there was non-response to phone calls. This was done for patients whose residence
was within 21 km radius of the health facility. Patients were classified as lost to follow-up if
they didn’t attend the clinic for a scheduled appointment or drug pickup more than 90 days
after the missed appointment/drug pick up and there was no information to classify them in
one of the other endpoint categories of death or transfer-out. At the time of enrolment (T1),
patient information was abstracted from the medical records. This included socio-demo-
graphic variables, past ART exposure; ART regimen prescribed and date of ART initiation,
CD4 T-cell count andWHO clinical stage. Plasma was extracted from whole blood taken at
participant enrolment, (or if not available, a freshly drawn venous sample), for VL and geno-
typic HIVDR testing conducted at the WHO-accredited MRC/UVRI laboratory in Entebbe.
HIV-1 Virological Failure and Antiretroviral Resistance in Ugandan Patients
PLOS ONE | DOI:10.1371/journal.pone.0145536 December 23, 2015 3 / 18
All plasma specimens at enrolment were collected on the day ART was prescribed for the
patient, but before the patient consumed any dose.
A second set of non-laboratory information was collected from medical records at follow-
up, (T2) i.e., either when first-line ART ended for the individual at the monitoring site, or at 12
months, if the individual was still alive and on a first-line regimen. The information included
drug pick-up during the previous 12 months, changes in regimen, adherence, and clinical sta-
tus at 12 months, i.e., whether the individual died, transferred out, became LTFU, stopped
ART, was switched to second-line ART, or was still on first-line ART at T2. At the follow-up,
we collected plasma for VL estimation, for those who switched to second-line regimen, at the
time of the switch, and from those who were alive and on first-line regimen at the end of the 12
months period. Specimens with a detectable VL (plasma RNA1000 copies/ml) were geno-
typed to detect and characterize DR mutations (DRMs).
The three sites were Masaka, Mbale regional public referral hospitals in the southern and
eastern parts of the country respectively and Nsambya Home-Care ART services, an NGO hos-
pital in Kampala. Nsambya’s support is mostly from the Presidents Emergency Plan for AIDS
Relief (PEPFAR) through Catholic Relief Services.
The HIVDR local database developed by WHO and US Centres for Disease Control and
Prevention Global AIDS Program was used for specimen tracking and data management.
Ethical clearance was obtained from the Uganda Virus Research Institute (UVRI) Science
and Ethics Committee (SEC) and the Uganda National Council for Science and Technology
(UNCST). Following written informed consent approved by SEC and UNCST, we enrolled
HIV-infected adults (at least 18 years of age) eligible for ART and commencing standard first-
line triple ART drug regimen for the first time. We excluded non-ART naïve individuals, i.e.,
adults who were taking or had previously started and stopped a standard first-line ART drug
regimen. Adults exposed to ART, either during ARV prophylaxis for prevention of mother-to-
child transmission or other mono or dual ART prophylactic regimens were eligible for
enrolment.
Sample size
At least 96 adults at each site with classifiable HIVDR outcome by 12 months of follow-up
were required to give an estimate of the proportion of adults with HIV DR prevention at 12
months with a 95% CI of +/-10% irrespective of the incidence of HIV DR prevention at each
monitoring site. We used consecutive sampling with all eligible adults for whom ART was initi-
ated till the required sample size of 140 clients had been attained at each site (The detailed for-
mula is under support document S1 Appendix).
Viral Load Testing and Genotyping
Stored plasma samples obtained at enrolment and follow-up were assayed for HIV-1 RNA
using the CAP/CTM (Cobas Ampliprep/Cobas Taqman 48) version 2 with a lower detection
limit of 20 copies/mL. Samples with HIV-1 RNA1000 copies/mL were sent for genotyping,as
guided by the WHO surveillance protocol.
Viral RNA was extracted from 140ul of plasma using the QIAmp Viral RNA mini kit (Qia-
gen). The entire protease (codons 1–99) and amino terminus of reverse transcriptase (codons
1–320) were amplified using one-step RT-PCR kit (Qiagen); briefly 10ul extracted RNA was
mixed with 6.5ul distilled water,5ul 5x PCR buffer (Invitrogen), 1ul dNTPS (Qiagen), 0.75 ul
forward primer POLF-1 (5’-TGAARGAITGYACTGARAGRCAGGCTAAT-3’),0.75ul reverse
primer POLR-1 (5’-CCTCITTYTTGCATAYTTYCCTGTT-3’) and 1ul enzyme mix (Qiagen).
The mixture was cycled for 50°C 40 min, 95°C 15 min, [94°C 30 s, 53°C 30 s, 72°C 1min] x 35
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cycles, 72°C 4 min and 10°C hold. Next 2ul of 1° PCR product was mixed with a master mix
containing 36.5ul distilled water, 5ul 10x PCR buffer (Invitrogen), 2ul Mgcl2 (Invitrogen), 1ul
dNTPs (Qiagen), 1.5ul forward primer POLF2 (5’-CTTTARYTTCCCTCARATCACTCT-3’),
1.5ul reverse primer POLR2 (5’- GGCTCTTGATAAATTTGATATGTCCAT-3’) and 0.5ul of the
platinum Taq enzyme (Invitrogen) this was cycled at 95°C 5min, [94°C 30 s, 50.3°C 30 s, 72°C
1min]x 35 cycles, 72°C 2 min and 4°C hold. Gel electrophoresis was done using 1% agarose gel
to ascertain the right size of the amplified PCR product. The right size PCR product was
cleaned using QIAquick PCR purification kit using manufacturer’s instructions. The cleaned
products were sequenced using the Big dye terminator v3.1 cycle sequencing kit (Applied Bio-
systems) in a reaction of 4ul of the DNA template, 6ul distilled water,2.5ul ready reaction mix,
3ul 5x SEQ buffer, 5ul of each of 3 forward primers B (5’-GTTAAACAATGGCCATTGACAG
AAGA-3’), C(5’-TGGAAAGGATCACCAGCAATATTCCA-3’) and POLF2(5’-CTTTARYTTCCCT
CARATCACTCT-3’) and 3 reverse primers; F (5’-GGGCCATCCATTCCTGGC-3’), G (5’-
CCATCCCTGTGGAAGCACATTG-3’) and H (5’-CTGTATTTCTGCTATTAAGTCTTTTGA-3’).
Cycle sequencing was performed using the following conditions 96°c for 1min [96°c for 20 s,
55°c 20 s, 60°c 4min] x 25 cycles, and 4°C hold. Sequencing was done using the ABI 3500
machine (Applied Biosystems). Sequences were base-called using Sequencher v5.2.4 and
sequence alignments performed using BioEdit v7.2.5 (T. Hail, 2013) and SeaView v4.0 (Gouy
M, Guindon S & Gascuel 0 2010). Quality Assurance was done using the Calibrated Population
Resistance tool (CPR), Stanford and the Los Alamos National database (LANL dbase) for the
HIV Sequence Quality Analysis.
DRMs classified as low, intermediate or high were assigned by submission of sequences to
Stanford HIVdb Program whereas HIV-l subtypes was done using SCUEAL and REGA online
software, (www.bioafrica.net/rega-genotype/html/subtypinghiv.html) and RIP (www.hiv.lanl.
gov/content/seguence/RIP/RIP.htmIL). Assigned DRMs were interpreted using 2009 WHO
list for epidemiological surveys alongside with the lAS 2014 Update of DRMs of HIV-1 [20].
Basic phylogenies were performed to determine sequence relatedness and to rule out
contaminations.
Statistical analyses
The outcomes of interest included baseline (T1) and follow-up (T2) factors classified according
to HIVDR outcome: HIVDR prevention; possible or potential HIVDR and HIVDR as defined
in the 2012 WHO protocol [5]. The following are the definitions of the above outcomes:
HIVDR prevention: The numerator includes people with viral load less than 1000 copies/ml
12 months after antiretroviral therapy initiation or at the time of switch to second-line therapy.
The denominator includes people receiving first-line antiretroviral therapy at 12 months with
classifiable viral load results + people switching to second-line antiretroviral therapy with clas-
sifiable viral load result + people lost to follow-up + people who stopped antiretroviral therapy
during the survey.
HIV Drug Resistance: The numerator includes people with a viral load greater than 1000
copies/ml 12 months after antiretroviral therapy initiation or at switch to second-line therapy
with HIV drug resistance. The denominator includes people receiving first-line antiretroviral
therapy at 12 months with classifiable viral load results + people switching to second-line anti-
retroviral therapy with classifiable viral load result + people lost to follow-up + people who
stopped antiretroviral therapy during the survey.
Possible / Potential HIV Drug Resistance: The numerator includes people with viral load
greater than 1000 copies/ml and no detected HIV drug resistance at 12-month survey endpoint
(on antiretroviral therapy at 12 months and at switch)+ people who stopped antiretroviral
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therapy + people lost to follow-up + people with unclassifiable viral load at 12-month survey
endpoint (on antiretroviral therapy at 12 months and at switch). The denominator includes
people on first-line antiretroviral therapy at 12 months with classifiable viral load results + peo-
ple switching to second-line antiretroviral therapy with classifiable viral load result + people
lost to follow-up + people who stopped antiretroviral therapy during the survey.
The above definitions can also be accessed at http://www.who.int/hiv/pub/drugresitance/
report2012/en/.
All statistical analyses were performed using STATA version 12 (StataCorp LP, Texas,
USA). Chi-square tests and Mann-Whitney-U tests were used to determine associations
between patient characteristics for categorical variables and for continuous variables, respec-
tively. This was done for HIVDRMs at both T1 and T2, and for viral failure (VF) (RNA viral
load1000 copies/ml) at T2.
VF and HIVDRMs prevalence rates with 95% confidence intervals (95% CIs) were calcu-
lated. Logistic regression was used to obtain independent predictors of HIVDR prevention, VF
and HIVDRMs at T2. Variables that had a p–value of less than 0.25 in simple analysis were
included in the adjusted logistic regression model. AORs, 95% CIs, and p-values were
calculated.
Results
Study flow
Of the 427 antiretroviral-naive patients screened, a total of 425 who met the study eligibility
criteria and consented to participate in the study were consecutively enrolled, started on ART
and followed-up for 1 year. Two individuals were excluded, one did not provide a sample for
baseline viral load testing and another was found to have previously been on ART. Fig 1 sum-
marises the study flow with numbers of patients who were censored for different reasons dur-
ing the 1 year follow-up.
Patients who missed their scheduled visits were followed up to ascertain their status. Some
of these had died or transferred to other ART treatment facilities while still on first-line regi-
mens. However, if the status remained unknown and the patients hadn’t attended the clinic
within the 2 months preceding the 12 month visit, and for another three months after the 12
month visit, they were considered lost to follow up. Patients lost to follow up contributed to the
denominator in estimating the proportion of patients with the outcomes HIV DR prevention,
potential HIVDR resistance and HIVDR. These patients were included in the analysis for HIV
drug resistance because they would have taken some doses of ART with HIV being exposed to
the ARVs and potentially having archived resistance.
Characteristics of the study population at Baseline
Of the 425 patients from 3 sites whose specimens were sent for VL and baseline resistance test-
ing (done when VL was1000 copies): 141 (33.2%) patients were fromMasaka, 143 (33.6%)
fromMbale, and 141 (33.2%) from Nsambya Home Care.
Table 1 shows the characteristics of the entire study population and also compares the
groups by facility. About 34% of the participants were male and the median age was 34 years.
Of the 282 females in the study, 5 (1.8%) had previously received ART for PMTCT; 3 of these
were fromMasaka RRH (2 on TDF/FTC/EFV and 1 on TDF/FTC/NVP). Two participants
were fromMbale RRH and were on TDF/3TC/NVP and AZT/3TC/NVP. None of these
women exhibited HIVDRMs at baseline. There was no other form of ART exposure identified
in the survey.
HIV-1 Virological Failure and Antiretroviral Resistance in Ugandan Patients
PLOS ONE | DOI:10.1371/journal.pone.0145536 December 23, 2015 6 / 18
The median baseline CD4+ count was 204 cells/μl, and the median baseline HIV-1 plasma
RNA level was 127,929 copies/ml.
Samples from 419(98.6%) patients had viral load 1000 copies/ml. Of these, 413 were suc-
cessfully sequenced. HIV-1 subtype profiles were: A1 46.5% (n = 192); C 4.3% (n = 18); D
38.5% (n = 159); Recombinants 10.7% (n = 44).
All patients received standard first-line ART regimens according to the Uganda National
guidelines at the time of enrolment into the survey, with 78.3% being initiated on a TDF con-
taining regimen. Two (0.5%) patients from Nsambya HC were prescribed a ritonavir boosted
lopinavir-based regimen as first-line because they had Kaposi’s sarcoma.
At baseline, drug resistance mutations (DRMs) were identified in 19(4.5%) of participants.
NRTI-associated DRMs and NNRTIs-associated DRMs were found in 9 (2.1%) and 17 (4.0%)
samples, respectively. Seven (1.7%) of the patients harboured mutations to more than one anti-
retroviral drug class, 3 (0.7%) had TAMs. None of the patients who exhibited DRMs reported a
history of ART exposure. The most common NRTI- associated mutation was M184V (33.3%)
Fig 1. Study profile: Of the 427 participants screened, 425 were enrolled and started on ART at the
three sites. Three hundred and twenty one participants completed their 12 months visit and had viral load
results available at baseline and month 12. Forty nine had viral loads equal or above 1000 copies/ml and
were genotyped. Of these 35 participants had HIV drug resistance mutations.
doi:10.1371/journal.pone.0145536.g001
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Table 1. Baseline Demographic, Clinical and Immunologic characteristics of patients receiving ART in three Sentinel Antiretroviral sites.
Characteristics Masaka n(%) Mbale n(%) Nsambya n(%) Total N(%)
Overall 141(100.0) 143(100.0) 141(100.0) 425(100.0)
Gender*
Male 59(41.8) 41(28.7) 43(30.5) 143(33.6)
Female 82(58.2) 102(71.3) 98(69.5) 282(66.4)
Age (years)*
Median (IQR) 32(28–37) 37(30–45) 33(27–40) 34(28–40)
Education Level
None 14(9.9) 33(23.1) 9(6.4) 56(13.2)
Primary 72(51.1) 54(37.7) 46(32.6) 172(40.5)
Secondary 38(27.0) 37(25.9) 51(36.1) 126(29.7)
Post-Secondary 2(1.4) 6(4.2) 18(12.8) 26(6.1)
No Information 15(10.6) 13(9.1) 17(12.1) 45(10.5)
Marital Status*
Single 11(7.8) 20(14.0) 31(22.0) 62(14.6)
Married 72(51.1) 87(60.8) 62(44.0) 221(52.0)
Separated 56(39.7) 34(23.8) 39(27.7) 129(30.4)
No Information 2(1.4) 2(1.4) 9(6.3) 13(3.0)
TB Treatment
No 132(93.6) 136(95.1) 129(91.5) 397(93.4)
Yes 8(5.7) 4(2.8) 11(7.8) 23(5.4)
No Information 1(0.7) 3(2.1) 1(0.7) 5(1.2)
CD4 Count (cells/μl)
Median (IQR) 203(81–301) 202(115–278) 208(84–314) 204(84–314)
Baseline WHO STAGE*
1 or 2 119(84.4) 104(72.7) 108(76.6) 331(77.9)
3 or 4 21(14.9) 37(25.9) 25(17.7) 83(19.5)
No Information 1(0.7) 2(1.4) 8(5.7) 11(2.6)
Subtype2*
A 51(37.5) 78(55.7) 63(46.0) 192(46.5)
C 6(4.4) 5(3.6) 7(5.1) 18(4.3)
D 69(50.7) 38(27.1) 52(38.0) 159(38.5)
AD 9(6.6) 19(13.6) 9(6.6) 37(9.0)
CD 1(0.8) 0(0.0) 6(4.3) 7(1.7)
Initial ART Regimen*
AZT+3TC+EFV/ NVP 1(0.7) 81(56.7) 8(5.7) 90(21.2)
TDF+3TC+EFV/ NVP 4(2.8) 62(43.3) 37(26.2) 103(24.2)
TDF+FTC+EFV/ NVP 136(96.5) 0(0.0) 94(66.7) 230(54.1)
AZT/TDF+3TC+KLT 0(0.0) 0(0.0) 2(1.4) 2(0.5)
ART exposure1*
No 134(95.1) 140(97.9) 128(90.8) 402(94.6)
PMTCT 3(2.1) 2(1.4) 0(0.0) 5(1.2)
No Information 4(2.8) 1(0.7) 13(9.2) 18(4.2)
HIV DR Mutations at Baseline
NRTI 5(3.5) 3(2.1) 1(0.7) 9(2.1)
NNRTI 7(5.0) 4(2.8) 6(4.3) 17(4.0)
At least One 8(5.7) 5(43.5) 6(4.3) 19(4.5)
RNA Viral Load (x105 copies/ml)
(Continued)
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out of the 15 NRTI mutations, whereas K103N and Y181C NNRTI mutations occurred at a fre-
quency of 35.0% and 25.0% respectively (n = 20). There were three PI accessory mutations
identified, two I85V and one F53L. These are unlikely to be ARV-selected and reflect natural
polymorphic behaviour of protease.
Analysis based on follow-up (T2)
The T2 characteristics of this cohort are shown in Table 2.
Out of the 425 patients enrolled, 20 (4.7%) patients had died, 66 (15.5%) were LTFU, 313
(73. 7%) were still on first-line, 8 (1.9%) had switched, 17 (4.0%) had transferred out (on first-
line regimen) and 1 (0.2%) stopped treatment.
Retention in care (patients who were still on first-line, switch and transferred-out) was
79.6% which was within the WHO threshold of 75–85% [16]. Only 56 (14.4%) patients picked
up their drugs on time, for at least 90% of the scheduled times during the 12 months follow-up
period. Masaka registered the highest number of patients who picked up their drugs on time
(p<0.001).
Of the 321 patients retained at 12 months, the median CD4 cell count was 325 cells/μl (IQR:
200–490), which increased significantly from the median of 204 cells/μl (IQR: 92–292) at base-
line (P<0.0001).
At T2, out of the 321 patients with VL results, 272 (84.7%) suppressed below 1,000 copies/
ml. However, using a denominator of 388 patients (which includes the patients still on first
line = 313, those LTFU = 66 and those who switched to second-line regimen = 8), the overall
HIV DR prevention rate was 272/388 (70.1%) due to LTFU and this was just within the recom-
mended WHO target of70%. At individual clinics these were 64.8% at Masaka, 73.1% at
Mbale and 72.3% at Nsambya (p = 0.28).
The proportion of participants with potential or possible HIVDR was 20.9% (81/388) which
is higher than the 18.8% based on pooled analyses from African studies [15] At individual clin-
ics these were, 22.6% at Masaka, 20.0% at Mbale and 20.0% at Nsambya (p = 0.22).
At T2, of the 19 patients with HIV DRMs at baseline: 1 died before the one year end point, 8
were LTFU, 3 were switched to second-line regimen, 2 were transferred out and 5 were still on
first-line regimen. After the 12 months of follow-up, all the three patients who were switched
to second-line regimen and only 1 out of the 5 who were still on first-line regimen achieved VL
suppression. The 4 patients who did not achieve VL suppression at follow-up, had HIVDRMs
and three of them accumulated additional mutations (data not shown).
The proportion of participants with HIVDR at T2 was 35/388 (9.0%), which is higher than
the 4.7% reported in the African region based on pooled analyses15. At individual sites, these
were 12.5% in Masaka, 6.9% in Mbale and 7.7% from Nsambya (Table 2). There was no signifi-
cant difference in the prevalence of mutations between sites at follow—up (p = 0.24).
Out of the 49 virologically failing therapy (1000 copies/ml) at 12 months, 35 (71.4%) had
HIVDRM, comparable to the 69.5% based on pooled analyses from Africa [16]
Table 1. (Continued)
Characteristics Masaka n(%) Mbale n(%) Nsambya n(%) Total N(%)
Median (IQR) 1.20(0.44–3.70) 1.49(0.53–4.20) 1.28(0.37–3.42) 1.30(0.47–3.76)
* Statistically signiﬁcant difference between facilities.
1PMTCT was the only form of ART exposure reported.
2only 413 samples successfully sequenced.
doi:10.1371/journal.pone.0145536.t001
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Of the 35 patients with mutations at T2, 80% had M184V/I, 65.7% Y181C and 48.6%
(54.8%, if those not on Tenofovir are excluded) had K65R mutations. There were 8/35 individ-
uals with TAMs (22.9%), (data not shown).
Predictors for HIV Drug Resistance Prevention and Mutations
The factors that were significantly associated with HIVDR prevention at 12 months were:
VL< 100,000 copies/ml at baseline (AOR 3.13, 95% CI: 1.36–7.19) and facility, with lower
HIVDR prevention at the Masaka site. (Table 3).
Independent predictors for HIVDRMs at 12 month were: CD4 count at baseline<250 cells/
μl (AOR 2.80, 95% CI: 1.08–7.29) and baseline VL100,000 RNA copies/ml had a borderline
association, (AOR 2.48, 95% CI: 1.00–6.14).(Table 4).
Considering only patients with VL results at follow-up, the factors that were significantly
associated with VF were: Facility, with higher VF at Masaka and base line VL 100,000 cop-
ies/ml (AOR 3.09, 95% CI: 1.34–7.11),; there was a weak association between VF and CD4
count at baseline<250 cells/ul (AOR 2.00, 95% CI: 0.91–4.35)and patients who picked up
drugs late (AOR 2.78, 95% CI: 0.86–9.00).(Table 5).
Discussion
This report, the first in Uganda to use a standardized WHO protocol to assess acquired drug
resistance, provides information on the performance of the treatment programmes at three
sites and associated factors, effectiveness of the current regimens and implications for second-
line in a programme setting. The study was also undertaken after the introduction of new treat-
ment guidelines with TDF as first drug of choice, prescribed to nearly 80% of the study
participants.
Table 2. Clinical and Virological characteristics of patients receiving ART in three Sentinel Antiretroviral sites at Follow-up.
Characteristics Masaka n(%) Mbale n(%) Nsambya n(%) Total N(%)
Status At Endpoint
Dead 8(5.7) 7(4.9) 5(3.5) 20(4.7)
Lost to follow-up 23(16.3) 23(16.1) 20(14.2) 66(15.5)
Still on ﬁrst line 103(73.0) 105(73.4) 105(74.5) 313(73.7)
Stop 0(0.0) 0(0.0) 1(0.7) 1(0.2)
Switch 2(1.4) 2(1.4) 4(2.8) 8(1.9)
Transfer—out 5(3.6) 6(4.2) 6(4.3) 17(4.0)
Drug Pick-Up
 90% On-time 35(27.3) 18(13.8) 3(2.3) 56(14.4)
RNA Viral Load (copies/ml)
<1000 83(79.0) 95(88.2) 94(86.2) 272(84.7)
1000 22(21.0) 12(11.2) 15(13.8) 49(15.3)
Potential HIVDR 29(22.6) 26(20.0) 26(20.0) 81(20.9)
HIV DR Prevention 83(64.8) 95(73.1) 94(72.3) 272(70.1)
HIV Drug Resistance 16(12.5) 9(6.9) 10(7.7) 35(9.0)
HIV DRMs at Endpoint
NRTI only 1(0.8) 1(0.8) 1(0.8) 3(0.8)
NNRTI only 0(0.0) 3(2.3) 1(0.8) 4(1.0)
Both NRTI & NNRTI 15(11.7) 5(3.8) 8(6.2) 28(7.2)
doi:10.1371/journal.pone.0145536.t002
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Table 3. Association between baseline patient characteristics and HIVDR Prevention at 12 Months after ART Initiation.
Characteristic HIVDR prevention** (%) Unadjusted OR (95% CI) P-Value Adjusted R*** (95% CI) P-Value
Gender
Male 110(84.6) 1 1
Female 229(88.8) 1.43(0.78–2.65) 0.25 1.17(0.59–2.37) 0.64
Age (years)
 30 123(89.1) 1 1
31–39 115(84.6) 0.67(0.33–1.36) 0.27 1.01(0.46–2.22) 0.98
40 99(89.2) 1.01(0.45–2.24) 0.98 1.38(0.55–3.43) 0.49
Education Level
None 43(86.0) 1
Primary 136(87.7) 1.17(0.46–2.96) 0.75
Secondary 101(88.6) 1.26(0.47–3.39) 0.64
Post-Secondary 24(92.3) 1.95(0.38–10.16) 0.43
No Information 35(81.4) 0.71(0.23–2.16) 0.55
Marital Status
Single 48(87.3) 1
Married 185(89.4) 1.22(0.49–3.04) 0.66
Separated* 96(84.2) 0.78(0.30–1.99) 0.60
No information 10(83.3) 0.73(1.13–4.04) 0.72
Facility
Masaka RRH 106(82.8) 1 1
Mbale RRH 118(90.8) 2.04(0.96–4.32) 0.06 2.73(1.22–6.36) 0.02
Nsambya 115(88.5) 1.59(0.78–3.23) 0.12 2.32(1.04–5.20) 0.04
TB Treatment
No 319(87.6) 1
Yes 16(84.2) 0.75(0.21–2.68) 0.67
Adherence Group
No 11(84.6) 1
Yes 321(87.7) 1.30(0.28–6.04) 0.74
CD4 Count (cells/μl)
<250 197(84.2) 1 1
250 138(92.6) 2.35(1.16–4.78) 0.02 1.81(0.82–4.00) 0.14
WHO Stage
3 and 4 57(80.3) 1 1
1 and 2 274(89.3) 2.04(1.03–4.05) 0.04 1.49(0.71–3.18) 0.29
HIV Subtype
A 151(86.3) 1
C 14(87.5) 1.11(0.24–5.20) 0.89
D 126(88.1) 1.17(0.61–2.29) 0.63
Recombinants 35(85.4) 0.93(0.35–2.44) 0.87
Drug Pick-up
Not On-time 287(86.5) 1 1
On-time 52(92.9) 2.04(0.70–5.91) 0.19 2.38(0.77–7.24) 0.14
ART Regimen
AZT+3TC+EFV/NVP 75(92.6) 1
TDF+3TC+EFV/NVP 84(90.3) 0.75(0.25–2.19) 0.59
TDF+FTC+EFV/NVP 179(84.4) 0.43(0.17–1.08) 0.72
Viral load (Copies/ml)
(Continued)
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We followed 425 patients from the three centers; these initiated treatment at relatively low
CD4 counts median of 204 cells/ul, a common observation in low income countries
[12,14,21,22]. The dominance of females initiating ART at all these sites possibly reflects the
general observed higher access to care by females that has previously been reported[23] and
the higher numbers of women infected in Uganda. The majority of patients were initiated on
the nationally recommended treatment regimens containing 1 NNRTI + 2 NRTIs whereas two
patients were started on PI-based regimen because they had Kaposis’s sarcoma. The HIV-1
subtypes observed reflect what has been reported before in these different parts of Uganda
[7,8,24]
About 4.5% of ART-naïve subjects initiating ART and with no reported prior ART exposure
had resistance mutations. This is slightly less than the 5.0% reported from low and middle
income countries [16] At baseline, NNRTI mutations were the most frequent at 4.0% followed
by NRTI at 2.1%. There were no PI mutations observed in this survey at baseline while 1.6%
had DRMs to more than one ART class. Three individuals had TAMs, known to lead to resis-
tance to multiple NRTIs. The presence of individuals with multiclass resistance and TAMs
may be a reflection of non-disclosed ART exposure, which is a challenge to ART roll-out since
it affects ART efficacy, although TDR is a possibility in some of these individuals.
There was good retention in care comparable to other studies, with 79.5% of patients
retained in care, which is above the WHO-required threshold of 70%; [16] all three sites met
this threshold. Our study showed an overall LTFU rate of 15.3%; WHO early warning indicator
guidance recommends that no more than 20% of patients should be LTFU 12 months after
treatment initiation.
Although 84.7% of participants with VL measurements at follow-up suppressed below 1000
copies/ml (Table 2), the overall HIVDR prevention rate was lower at 70.1% due to LTFU just
within the recommended WHO target of70%. At individual clinics, the Masaka site was
below this WHO threshold at 64.8%.
The above results coupled with the good CD4 recovery indicate that those who are retained
in care do well in terms of HIVDR prevention and immunological recovery; however at the
programme level HIVDR prevention is lower probably due to the LTFU.
At 12 months, overall 20.9% (Table 2) were classified as potential or possible HIVDR; this is
higher than 18.8% from a pooled analyses reported in the African region[16]. Our high rates
could again be largely due to the reported rates of LTFU at 15.3%. These individuals are more
likely to be non-adherent leading to DRMs.
The proportion of participants with HIVDRM at T2 was 9.0%(35/388), higher than the
4.7% reported in the African region based on pooled analyses of 239 patients failing therapy at
12 months [16] and two recent studies in Cameroon and Namibia that reported HIVDR preva-
lence of 5.3% and 5% respectively[14,15].
Table 3. (Continued)
Characteristic HIVDR prevention** (%) Unadjusted OR (95% CI) P-Value Adjusted R*** (95% CI) P-Value
100,000 164(94.2) 1 <0.001 1 0.01
<100,000 174(81.7) 3.68(1.78–7.68) 3.13(1.36–7.19)
*Either separated, divorced or widowed
** HIVDR prevention includes <1000 vl + LTFU + Stopped
*** only variables with p-value <0.25 and a priori confounders were included in this analysis
doi:10.1371/journal.pone.0145536.t003
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Table 4. Association between baseline patient characteristics and HIV Drug Resistance Mutations at 12 Months after ART Initiation.
Characteristic Mutations n(%) Unadjusted OR (95% CI) P-Value Adjusted OR** (95% CI) P-Value
Gender
Male 14(10.8) 1 1
Female 21(8.1) 0.73(0.36–1.50) 0.39 0.92(0.42–2.03) 0.84
Age (years)
 30 14(10.1) 1 1
31–39 11(8.1) 0.78(0.34–1.78) 0.51(0.21–1.27) 0.15
40 10(9.0) 0.88(0.37–2.06) 0.84 0.64(0.24–1.69) 0.37
Education Level
None 5(10.0) 1
Primary 13(8.4) 1.21(041–3.59) 0.73
Secondary 9(7.9) 1.30(0.41–4.08) 0.66
Post-Secondary 2(7.7) 1.33(0.19–7.39) 0.74
No Information 6(14.0) 0.69(0.19–2.43) 0.56
Marital Status
Single 5(9.1) 1
Married 16(7.7) 1.19(0.42–3.41) 0.74
Separated* 13(11.4) 0.78(0.26–2.30) 0.65
Unknown 1(8.33) 1.1(0.11–10.4) 0.93
Facility
Masaka RRH 16(12.5) 1 1
Mbale RRH 9(6.9) 0.52(0.22–1.22) 0.14 0.43(0.17–1.08) 0.07
Nsambya 10(7.7) 0.58(0.25–1.34) 0.20 0.52(0.21–1.24) 0.14
TB Treatment
No 33(9.1) 1
Yes 2(10.5) 1.18(0.26–5.33) 0.83
CD4 Count (cells/μl)
250 6(4.0) 1 1
<250 29(12.4) 3.37(1.36–8.33) 0.01 2.80(1.08–7.29) 0.04
WHO Stage
1 and 2 24(7.8) 1 1
3 and 4 11(15.5) 2.16(1.05–4.65) 0.04 1.62(0.71–3.74) 0.23
HIV Subtype
A 17(9.7) 1
C 2(12.5) 1.33(0.28–6.81) 0.72
D 13(9.1) 0.93(0.44–1.98) 0.85
Recombinants 3(7.3) 0.73(0.20–0.26) 0.64
Drug Pick-up
Not On-time 31(9.3) 1
On-time 4(7.1) 0.75(0.25–2.20) 0.59
Initial ART Regimen
AZT+3TC+EFV/NVP 4(4.9) 1
TDF+3TC+EFV/NVP 8(8.6) 1.81(0.52–6.26) 0.35
TDF+FTC+EFV/NVP 23(10.9) 2.34(0.78–6.70) 0.13
Viral load (Copies/ml)
<100,000 8(4.6) 1 1
(Continued)
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At T2, 71.4% (35/49)of the individuals virologically failing therapy had DRMs (Table 2)
very much comparable to the average pooled analyses from Africa [16]. This indicates that
most of the failure is due to resistance and a smaller proportion probably due to very low
adherence.
The resistance patterns seen in our study have been reported before in patients started on
these first-line regimen containing 3TC and FTC NRTIs and EFV, NVP NNRTIs [16,25].
K65R is now emerging following the recent introduction of TDF as a first-line drug in this sub-
type A and D infected population. K65R previously reported to be associated more with sub-
type C is a mutation associated with cross resistance to NRTI other than TDF and hence has
the potential to compromise NRTI backbones in the second-line. On the other hand the K65R
and the M184V increase AZT susceptibility which is one of the recommended second-line
NRTI. The Uganda guidelines recommend as second-line ART in adults 2 NRTIs and a ritona-
vir boosted PI. After failure on TDF + 3TC, use AZT+3TC; after failure on AZT+3TC, use
TDF + 3TC or ABC + 3TC. Boosted Atazanavir (ATV/r) is the preferred PI option for second-
line ART. There were (22.9%) 8/35 individuals with TAMs (data not shown), higher than in a
pooled analyses from 269 patients, where one or more TAMs were identified at 12 months in
15.6% of people being treated[16]. Again though TAMs are associated with reduced suscepti-
bility to a number of NRTIs, the second-line regimens in the above guidelines would be
effective.
In our study, factors associated with HIVDR prevention at 12 months were baseline
VL< 100,000 copies/ml and facility. Low baseline CD4 counts<250 and high VL 100,000
copies/ml were associated with presence of HIVDRMs at 12 months. Considering only patients
with VL results at endpoint, the factors that were significantly associated with VF were baseline
VL 100,000 copies/ml and facility. There was also a weak association between VF and CD4
count at baseline<250 cells/μl and patients who picked up drugs late.
The lower HIVDR prevention and higher VF in Masaka could be due to insufficient pre-
ART counselling provided by few counsellors per patients compared to the other two sites.
Masaka had three counsellors supporting an average of 100 new ART patients per month com-
pared to Mbale’s five counsellors for an average of 43 new ART patients and Nsambya’s seven
counsellors for an average of 50 new ART patients. The patient’s comprehension of the impor-
tance of adherence and overall readiness for ART is likely to be compromised and hence poorer
outcome for Masaka. Furthermore, this clinic engaged an additional cadre of lay health workers
as adherence counsellors to assist in providing ART specific counselling. Much as these health
workers received some basic training, the course was not accredited by the Ministry of Health
AIDS Control Programme, hence questionable quality.
To improve treatment outcomes and prevent HIVDR emergence, there is therefore a need
to enrol patients into care early enough and to have facility targeted interventions such as ade-
quate pre-ART counselling. WHO has recently revised the treatment guidelines recommend-
ing starting treatment in adults and adolescents with HIV at CD4 cut-off of<500 cells/mm3
Table 4. (Continued)
Characteristic Mutations n(%) Unadjusted OR (95% CI) P-Value Adjusted OR** (95% CI) P-Value
100,000 27(12.7) 3.01(1.33–6.77) 0.01 2.48(1.00–6.14) 0.05
*Either separated, divorced or widowed
** only variables with p-value <0.25 and a priori confounders were included in this analysis
doi:10.1371/journal.pone.0145536.t004
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Table 5. Association between baseline patient characteristics and Virological failure at 12 Months after ART Initiation
Characteristic VL 1000** Copies/ml (%) Unadjusted OR (95% CI) P-Value Adjusted OR** (95% CI) P-Value
Gender
Male 20(18.2) 1 1
Female 29(13.8) 0.73(0.39–1.36) 0.32 0.93(0.45–1.92) 0.85
Age (years)
 30 15(13.8) 1 1
31–39 21(18.3) 1.40(0.68–2.88) 0.36 1.01(0.45–2.26) 0.98
40 12(12.8) 0.92(0.41–2.17) 0.84 0.73(0.29–1.88) 0.51
Education Level
None 7(18.4) 1
Primary 19(14.1) 0.72(0.28–1.88) 0.51
Secondary 13(13.8) 0.71(0.26–1.95) 0.51
Post-Secondary 2(9.5) 0.47(0.09–2.48) 0.37
Unknown 8(24.2) 1.42(0.45–4.44) 0.55
Marital Status
Single 7(16.3) 1
Married 22(12.6) 0.74(0.29–1.87) 0.52
Separated* 18(19.0) 1.20(0.46–3.13) 0.71
Unknown 2(25.0) 1.71(0.29–10.3) 0.56
Facility
Masaka RRH 22(21.0) 1 1
Mbale RRH 12(11.2) 0.47(0.22–1.02) 0.06 0.37(0.16–0.85) 0.02
Nsambya 15(13.8) 0.60(0.29–1.24) 0.17 0.39(0.17–0.88) 0.03
TB Treatment
No 45(15.0) 1
Yes 3(20.0) 1.42(0.39–5.24) 0.60
Adherence Group
No 2(18.2) 1
Yes 45(14.9) 0.78(0.16–3.75) 0.76
CD4 Count (cells/μl)
250 11(8.9) 1 1
<250 37(19.2) 2.43(1.19–5.00) 0.02 2.00(0.91–4.35) 0.08
WHO STAGE
1 and 2 33(12.8) 1 1
3 and 4 14(26.4) 2.45(1.20–4.99) 0.02 1.18(0.80–3.89) 0.12
HIV Subtype
A 24(16.2) 1
C 2(20.0) 1.29(0.25–6.46) 0.76
D 17(14.1) 0.84(0.43–1.65) 0.62
Recombinants 6(18.6) 1.19(0.44–3.21) 0.72
Drug Pick-up
On-time 4(8.5) 1 1
Not On-time 45(16.4) 2.11(0.72–6.18) 0.14 2.78(0.86–9.00) 0.09
ART Regimen
AZT+3TC+EFV/NVP 6(9.23) 1
TDF+3TC+EFV/NVP 18(17.1) 2.03(0.76–5.42) 0.12
TDF+FTC+EFV/NVP 23(15.8) 1.84(0.04–0.24) 0.21
Viral load (Copies/ml)
(Continued)
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regardless of clinical stage, Uganda adopted these in early 2013, however patients continue to
enrol at low CD4 counts.
The only information we could collect on adherence at all facilities was whether or not a
patient had received pre-ART counselling recorded as adherence group and this did not affect
out-come measures, although the non-group numbers were very few.
Adherence assessment based on physical counts of pills remaining at the time patients
attend clinic for refill, and self-recall of missed doses during the previous month should be
recorded in the patient’s clinical cards at every visit. However, this was not always done. This
assessment was done at all visits for 16% and 58% of patients in Masaka and Nsambya sites
respectively and the majority (>90%) had good (of95%) adherence. Mbale data was unavail-
able because the facility used a manual register unlike the other two which used electronic med-
ical registers making it difficult to summarise data for all patients’ visits.
Gender, age at ART initiation, education level, marital status, PMTCT exposure, viral sub-
type and treatment regimens did not affect 12 months HIVDR prevention and HIVDR muta-
tion outcome.
Some of the limitations of the study include the non-generalizability of these results which
are more site specific rather than national or regional. In addition, 55 participants with low vir-
eamia 50-<1000 copies/ml were not genotyped, the WHO protocol excludes these yet there
could be HIVDR in these individuals as well.
Conclusions
There was good retention in care and a high percentage of these individuals had suppressed
VLs below 1000 copies/ml (84.7%). The overall HIV DR prevention rate at programme level
was just within the recommended WHO target of70%, and it was below this threshold at one
clinic. The proportion of participants with potential HIVDR (20.9%) and the proportion with
HIVDRM at 12 months (9.0%) were also overall higher than the average from other African
sites. This performance could be due to the LTFU and hence the need to strengthen defaulter
tracing to improve treatment outcome.
The second-line regimens recommended were appropriate, however, the high rate of the
K65R and TAMs is likely to compromise second-line drugs containing other NRTI backbone.
More advanced disease at ART initiation was associated with lack of suppression and HIVDR.
Efforts to initiate patients on treatment above CD4 250 cells/ul would contribute to improved
ART efficacy and HIVDR prevention.
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Table 5. (Continued)
Characteristic VL 1000** Copies/ml (%) Unadjusted OR (95% CI) P-Value Adjusted OR** (95% CI) P-Value
<100,000 10(20.4) 1 1 0.01
100,000 39(79.6) 3.68(1.76–7.66) 0.001 3.09(1.34–7.11)
*Either separated, divorced or widowed
** only variables with p-value <0.25 and a priori confounders were included in this analysis
doi:10.1371/journal.pone.0145536.t005
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